GoodRx Holdings annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
GoodRx Holdings R&D Spending Growth & History (GDRX)
GoodRx Holdings's r&d spending was $121.0M for fiscal 2025.
View full GoodRx Holdings company overviewGoodRx Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $121.0M | −$2.7M | −2.20% |
| 2024 | 2024-12-31 | $123.7M | −$12.1M | −8.90% |
| 2023 | 2023-12-31 | $135.8M | −$7.3M | −5.10% |
| 2022 | 2022-12-31 | $143.1M | $17.3M | +13.73% |
| 2021 | 2021-12-31 | $125.9M | $64.0M | +103.60% |
| 2020 | 2020-12-31 | $61.8M | $32.5M | +110.98% |
| 2019 | 2019-12-31 | $29.3M | −$14.6M | −33.25% |
| 2018 | 2018-12-31 | $43.9M | — | — |
GoodRx Holdings quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $26.7M | −$3.2M | −10.76% |
| Q1 2026 | 2026-03-31 | $30.2M | −$965,000 | −3.10% |
| Q4 2025 | 2025-12-31 | $28.9M | −$2.8M | −8.82% |
| Q3 2025 | 2025-09-30 | $31.0M | $873,000 | +2.90% |
| Q2 2025 | 2025-06-30 | $29.9M | −$921,000 | −2.99% |
| Q1 2025 | 2025-03-31 | $31.1M | $125,000 | +0.40% |
| Q4 2024 | 2024-12-31 | $31.7M | −$293,000 | −0.91% |
| Q3 2024 | 2024-09-30 | $30.1M | −$9.5M | −23.91% |
| Q2 2024 | 2024-06-30 | $30.9M | −$431,000 | −1.38% |
| Q1 2024 | 2024-03-31 | $31.0M | −$1.9M | −5.75% |
| Q4 2023 | 2023-12-31 | $32.0M | −$4.7M | −12.89% |
| Q3 2023 | 2023-09-30 | $39.6M | $3.7M | +10.27% |
| Q2 2023 | 2023-06-30 | $31.3M | −$4.1M | −11.63% |
| Q1 2023 | 2023-03-31 | $32.9M | −$2.1M | −6.09% |
| Q4 2022 | 2022-12-31 | $36.8M | $1.7M | +4.88% |
| Q3 2022 | 2022-09-30 | $35.9M | $848,000 | +2.42% |
| Q2 2022 | 2022-06-30 | $35.4M | $5.8M | +19.74% |
| Q1 2022 | 2022-03-31 | $35.0M | $8.9M | +33.95% |
| Q4 2021 | 2021-12-31 | $35.1M | $11.4M | +48.04% |
| Q3 2021 | 2021-09-30 | $35.1M | $19.2M | +121.34% |
| Q2 2021 | 2021-06-30 | $29.6M | $17.6M | +147.17% |
| Q1 2021 | 2021-03-31 | $26.2M | $15.8M | +153.37% |
| Q4 2020 | 2020-12-31 | $23.7M | — | — |
| Q3 2020 | 2020-09-30 | $15.8M | $8.0M | +102.01% |
| Q2 2020 | 2020-06-30 | $12.0M | — | — |
| Q1 2020 | 2020-03-31 | $10.3M | — | — |
| Q3 2019 | 2019-09-30 | $7.8M | — | — |
GoodRx Holdings r&d spending trends
Over the last five fiscal years, GoodRx Holdings's r&d spending increased from $61.8M to $121.0M, a change of $59.2M. The latest reported quarter, Q2 2026, shows $26.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GoodRx Holdings source filings ↗